Literature DB >> 7538601

Dramatic prostate specific antigen decrease in response to discontinuation of megestrol acetate in advanced prostate cancer: expansion of the antiandrogen withdrawal syndrome.

N A Dawson1, D G McLeod.   

Abstract

We report a dramatic decrease in prostate specific antigen in response to the discontinuation of megestrol acetate in a patient with progressive metastatic prostate cancer. Our case demonstrates that withdrawal responses may occur with steroidal and nonsteroidal antiandrogens.

Entities:  

Mesh：

Substances：

Year:  1995        PMID： 7538601

Source DB:  PubMed          Journal:  J Urol        ISSN： 0022-5347            Impact factor:   7.450


  18 in total

1.  [How should hormone therapy for castration-resistant prostate cancer be continued?].

Authors:  M Spahn; M Krebs
Journal:  Urologe A       Date:  2012-01       Impact factor: 0.639

Review 2.  Secondary hormonal manipulations in prostate cancer.

Authors:  Charles J Ryan; Eric J Small
Journal:  Curr Oncol Rep       Date:  2005-05       Impact factor: 5.075

Review 3.  Switching and withdrawing hormonal agents for castration-resistant prostate cancer.

Authors:  David Lorente; Joaquin Mateo; Zafeiris Zafeiriou; Alan D Smith; Shahneen Sandhu; Roberta Ferraldeschi; Johann S de Bono
Journal:  Nat Rev Urol       Date:  2015-01       Impact factor: 14.432

4.  Delayed antiandrogen withdrawal syndrome after discontinuation of bicalutamide.

Authors:  Andrew J Cowan; Yoshio Inoue; Evan Y Yu
Journal:  Clin Genitourin Cancer       Date:  2014-09-22       Impact factor: 2.872

Review 5.  Antiandrogens in prostate cancer.

Authors:  P Reid; P Kantoff; W Oh
Journal:  Invest New Drugs       Date:  1999       Impact factor: 3.850

Review 6.  Antiandrogen withdrawal syndrome associated with prostate cancer therapies: incidence and clinical significance.

Authors:  R Paul; J Breul
Journal:  Drug Saf       Date:  2000-11       Impact factor: 5.606

7.  Antiandrogen withdrawal in castrate-refractory prostate cancer: a Southwest Oncology Group trial (SWOG 9426).

Authors:  A Oliver Sartor; Catherine M Tangen; Maha H A Hussain; Mario A Eisenberger; Minoti Parab; Joseph A Fontana; Robert A Chapman; Glenn M Mills; Derek Raghavan; E David Crawford
Journal:  Cancer       Date:  2008-06       Impact factor: 6.860

8.  Identification of a new androgen receptor (AR) co-regulator BUD31 and related peptides to suppress wild-type and mutated AR-mediated prostate cancer growth via peptide screening and X-ray structure analysis.

Authors:  Cheng-Lung Hsu; Jai-Shin Liu; Po-Long Wu; Hong-Hsiang Guan; Yuh-Ling Chen; An-Chi Lin; Huei-Ju Ting; See-Tong Pang; Shauh-Der Yeh; Wen-Lung Ma; Chung-Jung Chen; Wen-Guey Wu; Chawnshang Chang
Journal:  Mol Oncol       Date:  2014-06-24       Impact factor: 6.603

Review 9.  Secondary hormonal manipulation of prostate cancer.

Authors:  K A Harris; E J Small
Journal:  Curr Urol Rep       Date:  2001-06       Impact factor: 3.092

10.  Comprehensive Analysis of AR Alterations in Circulating Tumor DNA from Patients with Advanced Prostate Cancer.

Authors:  Elisa M Ledet; Michael B Lilly; Guru Sonpavde; Edwin Lin; Roberto H Nussenzveig; Pedro C Barata; Mark Yandell; Rebecca J Nagy; Lesli Kiedrowski; Neeraj Agarwal; Oliver Sartor
Journal:  Oncologist       Date:  2019-11-11
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.